Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-12

Study Completion Date

2023-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pancreatic adenocarcinoma represents more than 90% of pancreatic neoplasms. Around 14000 new cases of pancreatic adenocarcinoma are being diagnosed each year in France and about 8.6% in Grand Est region. National incidence has doubled for men and tripled for women between 1982 and 2012. Pancreatic adenocarcinoma is the deadliest digestive cancer, with only 7 to 8% all stages 5-year survival. It will become the second deadliest in Europe, behind bronchopulmonary cancer.

Several risk factors have been identified such as diabetes, tobacco, chronic pancreatitis or obesity. However, a mismatch exists between incidence forecasts and actual risk factors knowledge. Several hypothesis plead for an environnemental cause.

Plant protection products oncogenetic effects are known and have been proved to be responsible for tumors, including haematological malignancies. Its role in pancreatic carcinogenesis is still poorly studied and show heterogeneous results. They do not allow to conclude for causality. Organochlorines is a specific subset of plant protection product that store in lipids during lifetime.

The aim is to study association between organochlorine concentration in adipose tissue with pancreatic adenocarcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.

NCT02072616

Circulating Tumor Cells Pancreatic Adenocarcinoma Circulating Tumor DNA (KRAS) +1 more

UNKNOWN PHASE3

PAncreatic Adenocarcinoma in Hospital

NCT01989624

Pancreatic Adenocarcinoma

COMPLETED

Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas

NCT04617457

Pancreatic Cancer Metastasis Surgery +1 more

RECRUITING PHASE2

PAN Alimentary Cancer Exhaled Breath Analysis

NCT06764641

Breath Test

RECRUITING

METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors

NCT05794048

Hepatocarcinoma Pancreatic Tumor

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Unicentric prospective case control study comparing organochlorine levels including patients diagnosed with a pancreatic adenocarcinoma undergoing a surgery allowing to collect an adipose tissue sample (10g).

Controls are adults with no pancreatic cancer (excluded by a 6 months old computed tomography excluding the probability of a pancreatic neoplasm), paired with cases upon age and body mass index, with a scheduled surgical procedure allowing to collect an adipose tissue sample without extending procedure length.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma Pancreatic Ductal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group "Cases"

patients with pancreatic adenocarcinoma

Group Type EXPERIMENTAL

Adipose tissue sampling during surgery and urine sampling

Intervention Type OTHER

Adipose tissue sampling during surgery and urine sampling

Group "Controls"

patients without pancreatic adenocarcinoma

Group Type OTHER

Adipose tissue sampling during surgery and urine sampling

Intervention Type OTHER

Adipose tissue sampling during surgery and urine sampling

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adipose tissue sampling during surgery and urine sampling

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Cases :

* patients diagnosed with a pancreatic adenocarcinoma, all stages allowed
* undergoing a surgery allowing to take a 10 grams adipose tissue sample

Controls :

* patients without a pancreatic neoplasm on a 6 months old CT scan before inclusion
* undergoing a surgery allowing to take a 10 grams adipose tissue sample

Exclusion Criteria

Cases :

* patients diagnosed with a pancreatic adenocarcinoma developed on IPMN or cystadenoma
* patient with a known genetic predisposition increasing pancreatic adenocarcinoma risk
* histopathology proof of a mixed neuroendocrine neoplasm
* no surgery allowing to take a 10 grams adipose tissue sample

Controls :

* patients with a pancreatic neoplasm on a 6 months old CT scan before inclusion
* no surgery allowing to take a 10 grams adipose tissue sample

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No